Lee H S, Song D H, Kim J H, Lee Y M, Han E S, Yoo K J
Department of Psychiatry, Yonsei University College of Medicine, Seoul, Korea.
Int Clin Psychopharmacol. 1995 Jun;10(2):67-72. doi: 10.1097/00004850-199506000-00002.
A 6 week double-blind placebo-controlled trial of cyproheptadine augmentation of ongoing haloperidol treatment was conducted in 40 chronic schizophrenic in-patients. Cyproheptadine augmentation, compared to administration of haloperidol with placebo, did not produce a statistically significant improvement in psychotic symptoms. Cyproheptadine augmentation caused significant reduction in the extrapyramidal symptoms, which supports the atypical profile of antipsychotics. As to the neuroendocrinological effect, cyproheptadine augmentation did not reduce the plasma prolactin level but did induce a decrease in the plasma cortisol level. Although long-term follow-up studies are needed to confirm the results, this study suggests that cyproheptadine augmentation may be effective in treating chronic schizophrenic patients who are intolerant of extrapyramidal side effects of conventional antipsychotics.
对40名慢性精神分裂症住院患者进行了一项为期6周的双盲安慰剂对照试验，以研究赛庚啶增强正在进行的氟哌啶醇治疗的效果。与氟哌啶醇加安慰剂给药相比，赛庚啶增强治疗在精神病症状方面未产生统计学上的显著改善。赛庚啶增强治疗导致锥体外系症状显著减轻，这支持了抗精神病药物的非典型特征。关于神经内分泌效应，赛庚啶增强治疗并未降低血浆催乳素水平，但确实导致血浆皮质醇水平下降。尽管需要长期随访研究来证实结果，但本研究表明，赛庚啶增强治疗可能对不耐受传统抗精神病药物锥体外系副作用的慢性精神分裂症患者有效。
